Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Humacyte's Human Acellular Vessel in Life- or Limb-threatening Vascular Trauma
2020-003383-12Phase 2Terminated
- Sponsor
- Humacyte
- Start
- May 2021
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acellular tissue engineered vessel in vascular injury and arterial injury, sponsored by Humacyte. Primary endpoint: Safety. Started May 2021; status: terminated.
02
Drugs
acellular tissue engineered vessel
03
Conditions
vascular injuryarterial injury
Beyond the preview
Go deeper on 2020-003383-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003383-12.